Pfizer (PFE) Long-Term Debt Repayments (2009 - 2025)

Pfizer (PFE) has reported Long-Term Debt Repayments for 17 consecutive years, with $3.0 billion the latest figure, recorded in Q4 2025.

• On a quarterly basis, Long-Term Debt Repayments changed N/A year-over-year to $3.0 billion in Q4 2025; TTM through Dec 2025 was $6.8 billion, a N/A change from a year earlier, with the FY2025 full-year figure at $6.8 billion, up 200.31% from the prior year.
• Long-Term Debt Repayments was $3.0 billion for Q4 2025 at Pfizer, down from $3.8 billion in the prior quarter.
• Over five years, Long-Term Debt Repayments peaked at $3.8 billion in Q2 2025 and troughed at $269.0 million in Q2 2023.
• A 5-year average of $1.7 billion and a median of $1.2 billion in 2024 frame the typical range for Long-Term Debt Repayments.
• Across the five-year window, Long-Term Debt Repayments plunged 83.28% in 2023 and soared 364.68% in 2024, its largest moves.
• Over 5 years, Long-Term Debt Repayments stood at $1.0 billion in 2021, then jumped by 60.74% to $1.6 billion in 2022, then tumbled by 37.85% to $1.0 billion in 2023, then jumped by 125.0% to $2.2 billion in 2024, then surged by 33.64% to $3.0 billion in 2025.
• The last three Long-Term Debt Repayments figures came in at $3.0 billion (Q4 2025), $3.8 billion (Q2 2025), and $2.2 billion (Q3 2024), per Business Quant data.